Finans

Goldman dybdeanalyse om COVID testing, behandlinger og vaccine

Morten W. Langer

onsdag 29. april 2020 kl. 19:35

Fra Zerohedge/ Goldman
Hot on the heels after positive-sounding news on Gilead’s anti-viral therapy drug Remdesivir, Salveen Richter, GS lead analyst for the US Biotechnology sector, answers key questions on where we are on US testing, treatments and vaccines for COVID-19.

Q: What are the different ways that healthcare companies are tackling COVID-19?

A: As the impact of the COVID-19 pandemic on the global economy and modern-day society continues to unfold, diagnostics (testing for infection), treatments (to treat symptoms of COVID-19) and prophylactic vaccines (to prevent infection of SARS-CoV2—the virus that causes COVID-19) are being developed. There are primarily two types of diagnostic tests: molecular and serological.

While molecular tests quantify the presence of viral infection (implies infection), serological tests detect the presence of antibodies to coronavirus in the blood (implies immunity). Of the ~49 diagnostic tests approved by the FDA under its emergency use authorization (EUA), over 80% are molecular. However, as state and federal policy makers begin to think about restarting the economy, serology tests with high specificity are becoming a focus.

Q: What progress have we made in ramping up diagnostic testing capacity in the US and globally, and where are we still falling short?

A: The global capacity for molecular diagnostic testing of COVID-19 is now at ~30 million tests per month. While the current testing capacity is not sufficient to meet the entire demand on a population basis, we note an improvement in testing in the US over the past few weeks according to the COVID Tracking Project, from a total of 866 tests as of March 4 to 4.7 million tests as of April 23—largely driven by the FDA’s flexibility towards labs and manufacturers in this time of crisis.

We expect the FDA’s decision to implement its EUA (emergency use authorization) on in vitro diagnostics for the detection and/or diagnosis of COVID19 will continue to accelerate testing efforts. The FDA emergency use guidelines relax the standards that allow tests to be available, in part by expediting review timelines to as little as one day and allowing labs to begin testing prior to FDA review of the validation data.

But while the increase in available tests represents meaningful progress compared to the past couple of weeks, the availability of resources, including swab samples and trained professionals to collect these samples, and testing turnaround times continue to hinder the widespread scale up and availability of testing. Errors in the tests themselves, such as false negatives, present an additional hurdle for diagnosing COVID-19. As capacity for testing increases, it will be key to delineate between testing for the presence/absence of the actual infection, where there was meaningful progress in March, and testing for immunity generation, which will be relevant going forward.

A: Serological testing (i.e. presence of antibodies) can provide insight into herd immunity (the resistance to the spread of disease within a population resulting from a sufficiently high proportion of individuals immune to the disease), which is important because
once approximately >60% of the population is immune to the virus, a “next wave” of infections stemming from the same version of the virus is unlikely.

Several companies are developing antibody tests to measure the markers of an immune response to COVID-19, namely immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies. IgM antibodies are the first to appear in response to the initial exposure of a viral infection, and they begin to fade after the infection ends. As the body clears the
infection, there is an increase in IgG antibodies, which provide long-term immunity.

Thus, COVID-19 IgM antibodies may indicate more recent exposure to the virus, and the detection of COVID-19 IgG antibodies may indicate a later stage of infection. In order
to determine the stage of infection, it is therefore critically important to have a highly specific test that identifies the specific antibody present rather than a highly sensitive test that quantifies levels of the antibody. To that end, we highlight two serological
tests: Abbott’s, which has a specificity and sensitivity of 99.6% and 86.4%, respectively, and Roche’s, which has a specificity and sensitivity of >99% and >95%, respectively.

Based on the different proposed plans for the path forward in the US, we estimate the country would need an estimated 50 to 100 million antibody tests per month. In the US, Abbott committed to shipping 4 million tests in April, ramping to 20 million tests in June, and notes that its testing instruments can run up to 100 to 200 tests per hour. Roche is currently working with the FDA for an EUA on its tests, and plans to reach a capacity of 100 million tests per month by June, with a goal to ramp up further towards year-end. According to Roche, its instruments can run up to 300 tests per hour, depending on the analyzer used.

Q: What are the most promising types of treatments for active cases being developed right now, and what is a realistic timeframe for having an effective treatment widely available?

A: In broad terms, treatments for COVID-19 include approved drugs that can be repurposed, antiviral therapies that counteract the virus, antibody therapies that introduce neutralizing antibodies against the virus and convalescent plasma therapies, in which plasma from convalescent patients is administered to those infected.

On the therapeutic side, Gilead’s remdesivir and Regeneron’s antibody cocktail are most in focus. Gilead’s remdesivir is an Nuc inhibitor that terminates viral replication by preventing the function of RNA-dependent RNA polymerases (an enzyme that catalyzes the replication of RNA), resulting in a decrease in viral RNA production. 

Thus far, there has been emerging data for remdesivir in COVID-19 but we await full Phase 3 results in late April (for severe patients), late May (for moderate patients) and data from the NIAID sponsored study in mid-to-late May to elucidate the profile of the drug.

 

As it relates to symptomatic relief of COVID-19, anti-IL6 inhibitors are in development, with Roche’s Actemra in a Phase 3 trial (data in 2H20, potentially in the summer) and Regeneron/Sanofi’s Kevzara currently in Phase 2/3 testing. On the latter, going forward, the Phase 3 trial will only include “critical” patients with results (US) expected in June and the rest of the global studies in 3Q20. We also highlight Grifols, Takeda and CSL Behring, all of which are independently developing a novel convalescent plasma therapy against COVID-19. One potential limitation of this approach is the requirement of donor plasma, which could limit its scale.

Q: What are the most promising vaccines currently in development, and what is the earliest timeline we can expect to see for getting a vaccine to the public?

A: With several vaccines in development, we believe Moderna’s mRNA-based vaccine (mRNA-127) and Johnson & Johnson’s vaccine candidate, which uses established and validated AdVac technology, are the leading contenders to address the public health needs of the global community.

Moderna has previously issued guidance on the potential for emergency vaccine use in primary populations (including physicians) as early as fall 2020, following the release of Phase 1 safety data in the spring and immunogenicity data in the summer and Phase 2 initiation in 2Q20. We expect Johnson & Johnson to initiate Phase 1 trials in September, with topline safety and immunogenicity data expected by the end of 2020, and note the vaccine could be available under EUA in early 2021.

Q: Will any vaccine need to be administered every year, like a flu vaccine, or will it be effective over a multi-year period?

A: On the duration of efficacy, it is unclear if the COVID-19 vaccine will be similar to the yearly flu vaccine or whether it will be able to confer multi-year efficacy. While some experts believe multi-year protection is likely, more research is needed to determine if this is the case based on what we know about similar viruses. Using the 2002 SARS and 2012 MERS epidemics as analogs is not helpful in this case because there is not much known about their reinfection rates given the limited epidemiological details of both – there were >8,000 cases of SARS over 3 months, and only 2,500 observed cases of MERS over 8 years.

Del på facebook
Del på twitter
Del på linkedin
Del på email
Del på print

[postviewcount]

Formue

ØU Trader: Porteføljen fortsætter opad, slutter ugen i + 36% i 2020

Økonomisk Ugebrevs Portefølje ligger for 2020 aktuelt med et afkast på 36,0% – mod Copenhagen Benchmark på 30,6%. Altså 5,4 procentpoint bedre end benchmark. Den sidste del af porteføljens…
Samfundsansvar
Nordisk pensionssektor en af de mest transparente i EU
Samfundsansvar
Usikkerhed om EU Green Deal gift for Rockwools potentiale
Samfundsansvar
Intelligent skideballe til erhvervslivets CSR-indsatser
Samfundsansvar
Klimaplan skaber tvivl om aftale med Aalborg Portland
Samfundsansvar
EU Ombudskvinde: Kommissionen fejlede ved at hyre BlackRock som ESG-rådgiver
Finans
Genetablerede KPMG kan snart være tilbage i dansk Big Four
Finans
Store revisionshuse får flere kunder, trods øget fravalg af revision
Finans
Ekspertforslag: Sådan undgås skæve værdier på pensionssektorens alternativer
Finans
Hvornår løber Waturus pengekasse tom?
Samfundsansvar
Regeringens udspil til Grøn Skatterefom
Finans
Parken høster stort skjult sommerhus-guldæg næste år
Samfundsansvar
Podcast fra P4: ØU-redaktør om ny database for kontroversielle investeringer
Formue
Langers Skarpe Aktietips: Nu skal man tænke både kortsigtet og langsigtet
Samfundsansvar
Nasdaq køber firma til afsløring af finansiel kriminalitet og hvidvask

Seneste nyt

Finans
Slemme røde tal i Vækstfondens ventureportefølje
Samfundsansvar
EU-strategi for vedvarende offshoreenergi
Ledelse
Andelen af kvindelige ledere vokser, men ikke i topledelsen
Samfundsansvar
Kun et dansk selskab på nyt Dow Jones Sustainability Index
Samfundsansvar

ATP skærper investeringsstrategi overfor kulindustri

ATP er én af seks danske investorer på den tyske NGO Urgewalds nyopdaterede Coal Exit List, som kortlægger store investorers exitpolitik fra kulinvesteringer. ATP strammede i foråret sin eksklusionspolitik…

Aktuel artikelserie

Trænger First North vækstbørsen til en opstramning?

Chefredaktør Morten W. Langer har i en artikelserie påpeget en stribe huller i NasdaqOMX’s arbejde med at skabe en dansk vækstbørs, investorerne kan have tillid til. Selskaber som Conferize og NPinvestor har fra start været baseret på ekstremt svage forretningsmodeller og overvurderede værdiansættelser. Aktuelt viser sagen om Waturu, at institutionen med Certified Advisors ikke fungerer godt nok, når det gælder sikring af fyldestgørende information til investorerne. Baggrunden for ØU’s fokus på First North er, at en velfungerende dansk vækstbørs er samfundsmæssig vigtig som formidler af risikovillig kapital til små vækstvirksomheder.

Andre artikelserier

Dilemmaer i det aktive ejerskab
Finansiering af den grønne omstilling
Sustainable Finance: Nye spilleregler for den finansielle sektor
Nye krav til bestyrelsen i kølvandet på Coronakrisen
Hvilke strategier sikrer den bedre performance under coronakrisen?
Den danske banksektors lange vej mod konsolidering?
Ledelse
Kapitalismen skal tæmmes, ikke slås ihjel
Formue
Børshandel startet i Huscompagniet: Emissionsbanker holder hånden under aktien
Samfundsansvar
Analyse: ESG ratings forvirrer investorer om reel bæredygtighed
Formue
Aktieanalyse: Spirende optimisme hos Novo Nordisk
Finans
Qudos: Aarhusianske finansfolk stod bag kæmpe forsikringskonkurs med milliardtab
Samfundsansvar
Investeringsdirektør i PFA: Med Joe Bidens valgsejr i USA vil den grønne transformation tage fart
Finans
HusCompagniet klemmer citronen med slap vækststrategi
Finans
Optræk til stærkt comeback til SAS, efter mere corona
Formue
S&P Future: Så kom startsignalet til det næste aktierally
Samfundsansvar
ATP kræver mere specifikke skattepolitikker af virksomheder
Formue
MSCI: Europæiske aktier har givet minus 5% i afkast i år, Danmark +30%
Samfundsansvar
Investorer opfordrer europæiske virksomheder til at vise ‘manglende’ klimaomkostninger
Samfundsansvar
Læger uden Grænser: Aftaler om vacciner skal lægges frem for offentligheden
Ledelse
En verden til forskel: 20 år med god selskabsledelse

Seneste nyt

Formue
S&P Future står foran megastærkt aktierally – eller en flad udvikling med rotation
Formue
Finanshus går mod uberbullish udsigt: “Reopning Rotation Story is bearish”

Mest læste

Få dit daglige nyhedsoverblik i din indbakke

Seneste rapporter fra eksterne rådgivere

EU-Domstolen: TV2 skal betale ulovligheds­renter for statsstøtte
Har du styr på din prismarkedsføring til Black Friday?
Aftale på plads: Lagerbeskatning af løbende avancer for ejendomsselskaber indføres
Dybdegående og original 
journalistik siden 1994

Økonomisk Ugebrev har i mere end 25 år leveret indsigtsfuld og dagsordensættende journalistik og analyser til læserne og den brede offentlighed. 

Vi tager ansvar for vores indhold og er tilmeldt:

KONTAKT

Telefonisk henvendelse: 70 23 40 10
Telefonerne er åbne alle hverdage fra: 10-15

Skriv til os på: [email protected]
Vi bestræber os på at besvare henvendelser indenfor 24 timer.

Økonomisk Ugebrev A/S
CVR-nr.: 31760623
Sundkaj 125, 3. sal
Nordhavn 2150

Log ind

Har du ikke allerede en bruger? Opret dig her.

Analyse af og prognoser for Fixed Income (statsrenter)

Direkte adgang til opdaterede analyser fra toneangivende finanshuse:

Goldman Sachs

Fidelity

Danske Bank

Morgan Stanley

ABN Amro

Jyske Bank

UBS

SEB

Natixis

Handelsbanken

Merril Lynch 

Analyse og prognoser for kort rente, samt for centralbankernes politikker

Links:

RBC

Capital Economics

Yardeni – Central Bank Balance Sheet 

Investing.com: FED Watch Monitor Tool

Nordea

Scotiabank

 

Log ind

[iteras-paywall-login paywallid="qwerty123"]
X